Prostate Cancer

Adding abiraterone acetate (ZYTIGA) to androgen deprivation therapy for the management of patients with metastatic castration-naïve prostate cancer does not increase medical resource utilization.

The treatment method may delay need for systemic therapy in men with oligometastatic prostate cancer.

Study findings bolster the idea that frequent repeat biopsies are unnecessary.

Learn about this and other products in the pipeline for prostate cancer and bladder cancer.

"Every effort should be made to reduce the cost of molecular testing and expand their access," writes Ashley Ross, MD, PhD.

A new study examining gene expression assays for stratifying prostate cancer risk is suggesting that it may be possible to develop lower-cost alternatives and expand access.

This article discusses the risk of depression and suicide in men, focusing on increased risk in men with genitourinary cancer and other urologic conditions.

The urologist argued that he did obtain informed consent to the injection treatment, noting that the patient had signed a document that explained that scars were a possible outcome.

“If the PRECISION study results hold up in future research, any time you can avoid an invasive procedure with risks, obviously that’s good for patients,” says one urologist.

While a recent study of salvage radical prostatectomy after focal therapy demonstrates satisfactory functional outcomes, oncologic outcomes were not as good as after primary RP, said researcher Jaime O. Herrera-Caceres, MD.

Recent data support the product’s use in protecting organs at risk for radiation exposure.

"This important study provides strong validation of the utility of multiparametric MRI of the prostate prior to initial biopsy," writes Badar M. Mian, MD.

"AS is very cost effective over the short term compared to prostatectomy and radiation, but there a number of factors may impact actual AS cost savings over the long term," writes Leonard G. Gomella, MD.

Active surveillance as an initial management strategy for men with low-risk prostate cancer results in cost savings compared with immediate treatment, regardless of the treatment chosen.

To help you sift the enormous scientific program and prioritize your schedule at the AUA annual meeting, the editors have called upon Urology Times’ editorial advisory board to identify the key research across multiple areas of the specialty.

The benefits of bilateral nerve-sparing procedures in men undergoing radical prostatectomy may be concentrated in those patients who have high sexual function at baseline.

Abiraterone acetate (ZYTIGA) should be considered a standard of care for newly diagnosed, metastatic, non-castrate prostate cancer, as should docetaxel (Taxotere), according to a new clinical practice guideline from ASCO.

Studies provide clear evidence to support MRI fusion biopsy’s use as the gold standard for men at risk for prostate cancer diagnosis following an initial negative biopsy.

Limitations of MRI fusion biopsy include its cost, interobserver variability, and low diagnostic accuracy for clinically significant cancer in the anterior prostate.

Evidence shows HIFU can provide cancer control outcomes comparable to those associated with radical prostatectomy or radiation therapy in properly selected patients.

Recommending either whole-gland or focal HIFU cannot be justified when their pros and cons are judged relative to the appropriate comparator.

There were significant improvements among those studied on the higher radiation dose in terms of biochemical failure and distant metastases, however.

Practicing urologists should consider the potential value of performing a multiparametric MRI for a biopsy in men with suspected prostate cancer based on results from the PRECISION trial, says Veeru Kasivisvanathan, MRCS.